Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Sells $171,360.00 in Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CEO Yuval Cohen sold 17,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the completion of the sale, the chief executive officer directly owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. This trade represents a 9.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Corbus Pharmaceuticals Stock Up 2.6%

CRBP stock opened at $9.76 on Thursday. The firm has a market capitalization of $182.22 million, a PE ratio of -1.58 and a beta of 2.59. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $7.12 and a twelve month high of $20.56. The stock’s 50 day moving average is $8.84 and its 200-day moving average is $9.07.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). On average, equities research analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 earnings per share for the current fiscal year.

Trending Headlines about Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Director Nishant C. Saxena purchased 2,600 CRBP shares for approximately $25,038 at an average price of $9.63, increasing his direct ownership by 3.45%. Insider buying can signal management confidence in the company’s valuation. SEC insider ownership filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, substantially above recent trading levels. The firm continues to model a return to profitability by 2030, although its estimates were lowered.
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the data showed no short position and no meaningful change, it provides little actionable signal for investors.
• Negative Sentiment: HC Wainwright cut EPS forecasts across 2026-2030, including 2026 to a loss of $6.11 per share from $4.99, 2027 to a loss of $6.83 from $5.66, and 2030 profit to $0.15 from $1.29. The revisions point to weaker near- and long-term earnings expectations despite the Buy rating.
• Negative Sentiment: CFO Sean Moran sold 12,000 shares for approximately $120,960, reducing his holdings by 12.41%. The sale may weigh on sentiment, although insider transactions do not necessarily indicate a change in the company’s outlook. CFO stock sale report
• Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate, reinforcing concerns about continued cash burn and execution risk for its clinical-stage pipeline.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRBP. Wedbush dropped their price target on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 27th. Mizuho reduced their price objective on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a research report on Tuesday, June 23rd. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. HC Wainwright dropped their target price on shares of Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Jefferies Financial Group cut their target price on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $41.12.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CRBP. Bank of New York Mellon Corp purchased a new position in shares of Corbus Pharmaceuticals in the 2nd quarter worth about $425,000. Seven Fleet Capital Management LP increased its holdings in Corbus Pharmaceuticals by 51.0% during the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after buying an additional 28,937 shares during the last quarter. Bank of America Corp DE increased its holdings in Corbus Pharmaceuticals by 53,592.3% during the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 13,934 shares during the last quarter. Royal Bank of Canada raised its position in Corbus Pharmaceuticals by 81.2% in the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 13,401 shares during the period. Finally, Exome Asset Management LLC raised its position in Corbus Pharmaceuticals by 67.8% in the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock worth $2,199,000 after acquiring an additional 94,593 shares during the period. 64.64% of the stock is currently owned by institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.